Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes (ALKS) appointed Anne C. Whitaker as a new independent member of its Board of Directors, expanding the board with a director who has extensive biopharmaceutical leadership experience.
Whitaker has previously served as chief executive officer of Aerami Therapeutics, Novoclem Therapeutics and Synta Pharmaceuticals, and held senior roles at Bausch Health, Sanofi and GlaxoSmithKline. She currently sits on the boards of publicly traded Basilea Pharmaceutica and ICON, as well as several private life sciences companies. Alkermes’ leadership highlighted her track record in driving growth, transformation and board-level decision-making as well suited to support the company’s commercial portfolio and neuroscience pipeline.
Alkermes (ALKS) launched the 9th annual Alkermes Pathways Research Awards program, offering competitive neuroscience research grants of up to $100,000 per project, with the stage one submission period running from Sept. 11 to Oct. 16, 2026.
The program continues to support work related to schizophrenia, bipolar I disorder and associated sleep and circadian disturbances, and now also includes narcolepsy types 1 and 2 and idiopathic hypersomnia. Early-career M.D., Ph.D. or equivalent investigators within five years of their initial academic appointment, or current post-doctoral fellows, affiliated with U.S. medical or research institutions may apply. Selected letters of intent will proceed to a full application phase from Nov. 15, 2026 through Jan. 5, 2027. Since 2018, the program has awarded about $2.9 million to 29 U.S. researchers.
Tortugas Neuroscience has appointed Jim Frates to its Board of Directors and named him Chair of the Audit Committee. Frates is a veteran biopharmaceutical finance executive who currently serves as chief financial officer of Amylyx Pharmaceuticals (AMLX) and previously spent more than two decades as CFO of Alkermes (ALKS).
Tortugas, launched in April 2026, is a clinical-stage CNS-focused biotech developing small molecule new chemical entities with differentiated mechanisms of action. Its in-licensed pipeline from Jiangsu Hansoh Pharmaceutical Group and Eisai includes potential treatments for schizophrenia, tinnitus, focal epilepsy, reversible encephalopathies and other high unmet-need CNS indications.
During Frates’ tenure at Alkermes, the company grew from a clinical-stage enterprise to an international commercial organization with multiple products, more than $1 billion in revenue and over 2,000 employees, and completed numerous acquisitions and financings. Frates expressed enthusiasm for supporting Tortugas’ leadership in advancing its clinical programs.
Alkermes (Nasdaq: ALKS) reported that data from its Vibrance-1 phase 2 study of alixorexton in adults with narcolepsy type 1 were published in The Lancet Neurology. The randomized, double-blind, placebo-controlled trial (n=92) tested once-daily 4 mg, 6 mg and 8 mg doses over six weeks.
Alixorexton achieved statistically significant improvements versus placebo in excessive daytime sleepiness on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with all doses reaching normative ranges at week six. Weekly cataplexy rate was significantly reduced in the 6 mg group. Treatment was generally well tolerated with no serious treatment-emergent adverse events. These phase 2 results support Alkermes’ global Brilliance phase 3 program in narcolepsy type 1 and 2. Alixorexton has FDA Breakthrough Therapy designation for NT1 and Orphan Drug designations in idiopathic hypersomnia and narcolepsy.
Alkermes (Nasdaq: ALKS) reported its financial results for the quarter ended June 30, 2026 and directed investors to its investor relations website for the full second quarter 2026 earnings press release and presentation.
The company will host a conference call and webcast at 8:00 a.m. ET (1:00 p.m. BST) on July 28, 2026, accessible via its investor website or by U.S. and international dial-in numbers. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a clinical pipeline targeting narcolepsy, idiopathic hypersomnia and other neurological disorders.
Alkermes (Nasdaq: ALKS) will host a conference call and webcast at 8:00 a.m. ET (1:00 p.m. BST) on July 28, 2026 to discuss its second quarter financial results. U.S. participants can dial +1 877 407 2988 and international callers +1 201 389 0923. The webcast player and slides will be available in the Investors section of Alkermes’ website.
According to Alkermes, a replay of the webcast will be accessible about two hours after the event via the company’s website. The company describes itself as a global biopharmaceutical business focused on neuroscience, with commercial products and clinical candidates for multiple psychiatric and neurological conditions.
Alkermes (Nasdaq: ALKS) reported interim results from an ongoing long-term extension study of alixorexton, an oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 (NT1) and type 2 (NT2). At week 24, roughly nine months after first dosing in the phase 2 parent trials, all NT1 dose groups achieved normative wakefulness on the Maintenance of Wakefulness Test, with mean sleep latency around 29 minutes, and Epworth Sleepiness Scale scores in the normal range.
In NT2, mean sleep latency reached about 18 minutes, and mean ESS was 8.9 at week 24 across participants. NT1 median weekly cataplexy rate declined versus baseline. Patient-reported cognition and fatigue shifted from moderate impairment at baseline to normal or mild ranges. No serious treatment-emergent adverse events were reported; common events included headache, urinary symptoms, insomnia and upper respiratory infections. About 90% of NT1 and 80% of NT2 LTE participants remained on treatment. Alixorexton continues in phase 3 Brilliance studies and the phase 2 Vibrance-3 IH study.
Alkermes (Nasdaq: ALKS) reported detailed phase 2 Vibrance-2 results for alixorexton in adults with narcolepsy type 2 (n=93). Once-daily alixorexton met dual primary endpoints at week 8, showing statistically significant, clinically meaningful improvements vs. placebo on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale.
Mean MWT latency rose from ~6 to up to ~16 minutes; most patients reported normal or mild sleepiness by week 8 and normal ESS scores by week 13. Exploratory fatigue and cognition measures improved, and alixorexton was generally well tolerated with no serious treatment-emergent adverse events. A global phase 3 Brilliance program in NT1 and NT2 is underway.
Alkermes (Nasdaq: ALKS) announced new orphan drug designations for alixorexton, an oral OX2R agonist for sleep disorders. The FDA granted ODD for idiopathic hypersomnia, and the European Commission granted ODD for narcolepsy.
Alixorexton, which previously received FDA Breakthrough Therapy designation for NT1, is in phase 3 Brilliance trials for NT1 and NT2 and the phase 2 Vibrance-3 study for IH, which Alkermes aims to complete this year. Orphan status in the U.S. and EU may provide tax credits, reduced fees, and up to seven to ten years of market exclusivity if approved.
Alkermes (Nasdaq:ALKS) will present 26 sleep-medicine abstracts at SLEEP 2026 in Baltimore, June 14–17, 2026. Highlights include detailed positive phase 2 Vibrance-2 data on investigational OX2R agonist alixorexton in narcolepsy type 2, and multiple studies of once-nightly LUMRYZ (sodium oxybate).
Presentations span phase 2 and phase 3 trial designs (Brilliance, REVITALYZ), real‑world LUMRYZ evidence (REFRESH), claims analyses on hypersomnolence disorders, and patient survey data on fatigue, cognition, and treatment preferences. LUMRYZ prescribing information emphasizes CNS depression, abuse/misuse risks, and REMS distribution requirements.